IDENTIFICATION AND MOLECULAR-GENETIC CHARACTERISTICS OF THE HEPATITIS B VIRUS AMONG HIV-INFECTED PATIENTS IN ARKHANGELSK

• Published in: Problems of Virology
• Main Authors: Y. V. Ostankova, A. V. Semenov, E. B. Zueva, A. A. Totolian
• Format: Article in Journal/Newspaper
• Language: English; Russian
• Published: Central Research Institute for Epidemiology 2019
• Subjects: chronic hepatitis b; hbv genotype; molecular epidemiology; coinfection hiv + hbv; Microbiology; QR1-502; Pasteur; Arkhangelsk
• Online Access: https://doi.org/10.18821/0507-4088-2019-64-3-105-111; https://doaj.org/article/a5805416e9bb4e2aaeacc410eb6fdfed

Aim. To estimate the prevalence and characterize the hepatitis B virus among HIV-infected patients with virological failure of antiretroviral therapy in Arkhangelsk. Material and methods. HBV markers determinations (HBsAg, anti-HBs IgG, anti-HBcor IgG, DNA HBV) were performed in isolates from blood plasma samples 64 HIV-infected patients with virological failure of antiretroviral therapy (viral load >50 IU / ml after 6 months of antiretroviral therapy or an increase in viral load after primary suppression of viral replication). For the detection of the hepatitis B virus, nucleic acids were isolated using the commercial kit «AmplePrime Ribo-prep». The virus presence analysis was performing by the polymerase chain reaction (PCR) method with hybridization-fluorescence detection in “real time” using the commercial set of «AmpliSens® HBV-FL». In the future, we used the method developed by the Saint-Petersburg Pasteur Institute, which allows detecting HBV in biological material with a low viral load. Results. HBsAg-negative (occult) HBV was detect in 28 (43.8%) HIV-infected patients. Only HBV genotype D was detected, and the HBV subgenotype D1 prevailed (39.3%) compared with the HBV subgenotype D2 (32.1%) and D3 (28.6%). Serological markers in 42.8% of patients with HBV DNA were founding. Two HBV isolates with drug resistance mutations in the polymerase gene, leaded to amino acid substitutions (L180M, M204V) associated with the resistance development to lamivudine, entecavir, telbivudine and tenofovir were identifying. Conclusion. The occult (HBsAg-negative) HBV high prevalence among HIV-infected patients suggests the need to use molecular-biological diagnostic methods to identify HBV, as well as to analyze the HBV drug resistance mutation before starting antiretroviral therapy for HIV.